» Articles » PMID: 33413654

Dual-energy CT Quantitative Parameters for Evaluating Immunohistochemical Biomarkers of Invasive Breast Cancer

Overview
Journal Cancer Imaging
Publisher Springer Nature
Specialties Oncology
Radiology
Date 2021 Jan 8
PMID 33413654
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2) and Ki67 are the most useful immunohistochemical biomarkers of invasive breast cancer. The purpose of this study is to investigate the possibility of quantitative parameters derived from dual-energy CT (DECT) to discriminate immunohistochemical biomarkers of invasive breast cancer.

Methods: This prospective study enrolled 120 patients with invasive breast cancer who underwent preoperative contrast-enhanced DECT for staging purposes from June 2019 to January 2020. DECT quantitative parameters, including normalized iodine concentration (NIC), the slope of the spectral Hounsfield unit curve (λ), and the normalized effective atomic number (nZ), were obtained from reconstructed images. DECT quantitative parameters were compared with the expression status, and the correlations with the value of immunohistochemical biomarkers were evaluated. Inter-observer reproducibility analysis was performed to assess the measurement reproducibility of quantitative parameters. The diagnostic performance of the quantitative parameters was analyzed by receiver operating characteristic curve.

Results: The ER-negative group tended to display higher venous phase NIC and nZ compared with the ER-positive group (individually, p = 0.003, 0.011; area under the curve [AUC] of 0.65, 0.60). The PR-negative group demonstrated higher arterial and venous phase NIC compared with the PR-positive group (individually, p = 0.022, 0.005; AUC of 0.63, 0.65). NIC was correlated negatively with the value of ER and PR expression (r = - 0.175 ~ - 0.265, p = 0.002 ~ 0.042). The HER2-positive group tended to display higher venous phase nZ than the HER2-negative group (p = 0.022; AUC of 0.59). The Ki67 high-proliferation group demonstrated higher arterial phase, venous phase NIC and nZ than the Ki67 low-proliferation group (p < 0.001 ~ 0.005; AUC of 0.67 ~ 0.75). Both the NIC and nZ were correlated positively with the value of Ki67 (r = 0.240 ~ 0.490, p < 0.001 ~ 0.014).

Conclusions: NIC and nZ derived from DECT could be used to discriminate expression status and may associate with the value of immunohistochemical biomarkers of invasive breast cancer.

Citing Articles

Dual-layer detector spectral computed tomography quantitative parameters for predicting pathological complete remission after neoadjuvant treatment of breast cancer.

Guo S, Wang D, Zhao Q, Bi Z, Li W, Zhu J Quant Imaging Med Surg. 2025; 15(1):149-163.

PMID: 39839024 PMC: 11744159. DOI: 10.21037/qims-24-511.


Prediction of Ki-67 expression in gastric gastrointestinal stromal tumors using histogram analysis of monochromatic and iodine images derived from spectral CT.

Liu X, Han T, Wang Y, Liu H, Deng J, Xue C Cancer Imaging. 2024; 24(1):173.

PMID: 39741326 PMC: 11686923. DOI: 10.1186/s40644-024-00820-6.


A prediction model based on dual-layer spectral detector computed tomography for distinguishing nonluminal from luminal invasive breast cancer.

Liu J, Wang L, Ai Z, Jian L, Yang M, Liu S Quant Imaging Med Surg. 2024; 14(12):8672-8685.

PMID: 39698719 PMC: 11651959. DOI: 10.21037/qims-24-598.


Preoperative prediction of Ki-67 expression in hepatocellular carcinoma by spectral imaging on dual-energy computed tomography (DECT).

Li C, Yue X, Chen S, Lin Y, Zhang Y, Liao L Quant Imaging Med Surg. 2024; 14(12):8402-8413.

PMID: 39698618 PMC: 11651942. DOI: 10.21037/qims-24-461.


Development and validation of a model based on preoperative dual-layer detector spectral computed tomography 3D VOI-based quantitative parameters to predict high Ki-67 proliferation index in pancreatic ductal adenocarcinoma.

Zeng D, Zhang J, Song Z, Li Q, Zhang D, Li X Insights Imaging. 2024; 15(1):291.

PMID: 39636501 PMC: 11621245. DOI: 10.1186/s13244-024-01864-9.


References
1.
Weidner N, Semple J, Welch W, Folkman J . Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma. N Engl J Med. 1991; 324(1):1-8. DOI: 10.1056/NEJM199101033240101. View

2.
Vazquez-Martin A, Colomer R, Menendez J . Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer. Eur J Cancer. 2007; 43(7):1117-24. DOI: 10.1016/j.ejca.2007.01.037. View

3.
Lee Y, Seo H, Je B, Kim S, Oh H . Benefit of dual-energy CT iodine overlay technique for T1-hyperintense brain lesion. Neurology. 2017; 89(13):1426-1427. PMC: 5649765. DOI: 10.1212/WNL.0000000000004424. View

4.
Zhang X, Zheng C, Yang Z, Cheng Z, Deng H, Chen M . Axillary Sentinel Lymph Nodes in Breast Cancer: Quantitative Evaluation at Dual-Energy CT. Radiology. 2018; 289(2):337-346. DOI: 10.1148/radiol.2018180544. View

5.
Al-Najami I, Beets-Tan R, Madsen G, Baatrup G . Dual-Energy CT of Rectal Cancer Specimens: A CT-based Method for Mesorectal Lymph Node Characterization. Dis Colon Rectum. 2016; 59(7):640-7. DOI: 10.1097/DCR.0000000000000601. View